European Society for Medical Oncology Congress

Nivolumab did not improve overall survival compared with gemcitabine or pegylated liposomal doxorubicin in platinum-resistant ovarian cancer; however, it was better tolerated, according to results presented at ESMO Virtual Congress 2020.

Final analysis results from the ICON8 trial confirmed that weekly dose-dense chemotherapy does not significantly improve progression-free survival or overall survival in patients with epithelial ovarian cancer.

KELIM, a model-based parameter from CA-125 kinetics, was an independent prognostic factor of progression-free survival for 5 years after first-line treatment in patients with ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

In this video, Jyoti D. Patel, MD, associate vice chair for clinical research and professor of medicine at Northwestern’s Feinberg School of Medicine, spoke with Healio about data from a phase 3 study in lung cancer included in the ESMO Virtual Congress 2020 presidential symposium.

In this video, Jyoti D. Patel, MD, associate vice chair for clinical research and professor of medicine at Northwestern’s Feinberg School of Medicine, discussed two presentations from the ESMO Virtual Congress 2020.

Adding maintenance olaparib to bevacizumab provided a benefit beyond first progression, with a substantial second progression-free survival benefit, in patients with newly diagnosed, advanced high-grade ovarian carcinoma, according to data presented at ESMO Virtual Congress 2020.

After a 5-year follow-up, almost half of patients with newly diagnosed BRCA-mutated advanced ovarian cancer were progression-free after receiving 2 years of maintenance olaparib, according to data presented at ESMO Virtual Congress 2020.

Patients with gynecologic cancers that responded to first-line platinum-based chemotherapy receiving niraparib did not show lower health-related quality of life compared with placebo, according to data presented at ESMO Virtual Congress 2020.

In this video, James Stevenson, MD, a medical oncologist and hematologist at Cleveland Clinic, highlighted findings from the PIONeeR trial, which was presented at ESMO Virtual Congress 2020.